SAVVY® (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Ghana
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this trial was to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female vaginal transmission of HIV infection among women at high risk. METHODOLOGY/PRINCIPAL FINDINGS: This was a Phase 3, double-blind, randomized, placebo-controlled trial. Participants made up to 12 monthly visits for HIV testing, adverse event reporting, and study product supply. The study was conducted between March 2004 and February 2006 in Accra and Kumasi, Ghana. We enrolled 2142 HIV-negative women at high risk of HIV infection, and randomized them to SAVVY or placebo gel. Main outcome measures were the incidence of HIV-1 and HIV-2 infection as determined by detection of HIV antibodies from oral mucosal transudate specimens and adverse events. We accrued 790 person-years of follow-up in the SAVVY group and 772 person-years in the placebo group. No clinically significant differences in the overall frequency of adverse events, abnormal pelvic examination findings, or abnormal laboratory results were seen between treatment groups. However, more participants in the SAVVY group reported reproductive tract adverse events than in the placebo group (13.0% versus 9.4%). Seventeen HIV seroconversions occurred; eight in participants randomized to SAVVY and nine in participants receiving placebo. The Kaplan-Meier estimates of the cumulative probability of HIV infection through 12 months were 0.010 in the SAVVY group and 0.011 in the placebo group (p = 0.731), with a hazard ratio (SAVVY versus placebo) of 0.88 (95% confidence interval 0.33, 2.27). Because of a lower-than-expected HIV incidence, we were unable to achieve the required number of HIV infections (66) to obtain the desired study power. CONCLUSIONS/SIGNIFICANCE: SAVVY was not associated with increased adverse events overall, but was associated with higher reporting of reproductive adverse events. Our data are insufficient to conclude whether SAVVY is effective at preventing HIV infection relative to placebo. TRIAL REGISTRATION: ClinicalTrials.gov NCT00129532.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755
Cited by
Skoler-Karpoff, S., Ramjee, G., Ahmed, K., Altini, L., Plagianos, M. G., Friedland, B., Govender, S., De Kock, A., Cassim, N., Palanee, T., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61842-5 · Cited by 502
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.
Feldblum, P. J., Adeiga, A., Bakare, R., Wevill, S., Lendvay, A., Obadaki, F., Olayemi, M. O., Wang, L., Nanda, K., & Rountree, W. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001474 · Cited by 280
Self-citationBiomedical interventions to prevent HIV infection: evidence, challenges, and way forward
Padian, N. S., Buvé, A., Balkus, J., Serwadda, D., & Cates, W. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60885-5 · Cited by 264
Inácio, Â. S., Mesquita, K. A., Baptista, M., Ramalho-Santos, J., Vaz, W. L. C., & Vieira, O. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019850 · Cited by 141
McCoy, S. I., Kangwende, R. A., & Padian, N. S. (2010) · AIDS and Behavior · doi:10.1007/s10461-009-9644-9 · Cited by 75
Metadata
- Authors
- Peterson, L., Nanda, K., Opoku, B. K., Ampofo, W. K., Owusu-Amoako, M., Boakye, A. Y., Rountree, W., Troxler, A., Dominik, R., Roddy, R., & Dorflinger, L.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-12-19
- Volume
- 2
- Issue
- 12
- Pages
- e1312
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1986445745
- Cited by
- 187
- References
- 2
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SAVVY® (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Ghana. https://app.cochat.ai/papers/10.1371/journal.pone.0001312
- The paper
- Peterson, L., Nanda, K., Opoku, B. K., Ampofo, W. K., Owusu-Amoako, M., Boakye, A. Y., Rountree, W., Troxler, A., Dominik, R., Roddy, R., & Dorflinger, L. (2007). SAVVY® (C31G) Gel for Prevention of HIV infection in Women: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Ghana. PLoS ONE. https://doi.org/10.1371/journal.pone.0001312
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.